Our results suggest that the CD19 CAR T cells derived from the HI19α clone are also capable of promoting high anti-leukemic efficacy and may be able to address issues associated with poor prognosis in R/R B-ALL patients. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.